作者
Rury R Holman, Ruth L Coleman, Juliana CN Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan, Joanne Keenan, Joanne Milton, Zoe Doran, Chris Bray, Jean L Rouleau, Jane Collier, Stuart Pocock, Eberhard Standl, Karl Swedberg, Jianping Weng, Dong Zhao, Mark C Petrie, Eugene Connolly, Pardeep Jhund, Michael MacDonald, Rachel C Myles, Rong Bai, Jing Li, Zhaoping Liu, Zhenyu Liu, Dantao Peng, Qiguang Tong, Chunxue Wang, Xiaowei Yan, Yuqing Zhang, Jingmin Zhou, Naveed Sattar, Miles Fisher, John R Petrie, M Angelyn Bethel, Wen Xu, Sarah Hearn, Anurag Kappai, Shu-Yi Su, Winitha Liyanage, Sanjoy Paul, Emanuela Pozzi, Arne Ring, Rajbir Athwal, Priyanka Batra, Andrea Ferch, Natasha Groves, Irene Kennedy, Olga Nawalaniec, Yash Patel, Rachel Roberts, Victoria Rush, Jayne Starrett, Jennifer Tang, Jing Bi, Zhe Jiang, Hua Wei, Xiaoshuai Wei, Xuan Zhang, Jun Yin, Yu Sun, Rong Hu, Yang Liu, Jianjing Long, Yuefeng Long, Guofang Qiao, Haoyi Qiao, Xiaochun Sun, Yucheng Zhang, Jing Zhou, Bangning Wang, Bin Chen, Lili Deng, Xiaoning Han, Taohong Hu, Qi Hua, Yanming Huo, Hongmei Li, Hongwei Li, Lihua Liu, Juming Lu, Changsheng Ma, Jianjun Peng, Lin Pi, Bin Wang, Guanglin Wei, Ming Yang, Shuyang Zhang, Likun Zhang, Xia Zhao, Yujie Zhou, Libin Shi, Mingsheng Wang, Lirong Wu, Lei Han, Ronghong Liao, Boli Ran, Qiang She, Jiancong Tan, Mei Xia, Chengming Yang, Lianglong Chen, Shangquan Xiong, Ling Yu, Xiaodong Pu, Yan Wang, Qiang Xie, Cibin Chen, Jiyan Chen, Yugang Dong, Zhaohui Wu, Yong Yuan, Wanxing Zhou, Shuxian Zhou, Xiaochao Chen, Chun Wu, Aidong Zhang, Zicheng Li, Shayi Lai, Jin Yang, Jinru Wei, Riyu Kuang, Zilin Zhao, Guoqiang Zhong, Xufen Cao, Yuming Hao, Gang Liu, Dongmei Wang, Hui Fang, Lingjun Kong, Haitao Li, Changqing Wang
发表日期
2017/11/1
期刊
The lancet Diabetes & endocrinology
卷号
5
期号
11
页码范围
877-886
出版商
Elsevier
简介
Background
The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced.
Methods
The Acarbose Cardiovascular Evaluation (ACE) trial was a randomised, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China. Chinese patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1), in blocks by site, by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular secondary …
学术搜索中的文章
RR Holman, RL Coleman, JCN Chan, JL Chiasson… - The lancet Diabetes & endocrinology, 2017